Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
Date:10/27/2008

CRANBURY, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce third quarter 2008 financial results after the regular close of markets on Monday, November 3, 2008. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. ET.

Interested participants and investors may access the conference call at 5 p.m. ET by dialing 877-419-6591 (U.S./Canada) or 719-325-4858 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. ET. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4499321.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at http://www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, a webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical n
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of ... the quarter ended June 30, 2015, corporate highlights, ... management report are available at www.sedar.com ,  ... "RepliCel expects to launch its ...
(Date:8/28/2015)... , ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) ... humor and excellent customer service. Images such as the Fonz in a lab coat ... some flavor to the humdrum spectroscopy field. , FireflySci is proud to be ...
(Date:8/27/2015)... VA (PRWEB) , ... August 27, 2015 , ... ... contractors solve complex business problems, is pleased to announce their ranking as one of ... annual ranking of the fastest-growing private companies across the nation. , “It is truly ...
(Date:8/27/2015)... 27, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today ... study of BHV-0223, a glutamate modulating agent. Biohaven ... and recently obtained clearance from the U.S. Food ... testing. Portage holds 54% equity interest in Biohaven, ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... ... Issues of Food and Drug Safety , ... Rockville, Md. (Vocus) September 29, 2009 -- Counterfeit and adulterated food and drugs ... Annual Scientific Meeting (ASM) hosted by the U.S. Pharmacopeial (USP) Convention. Held in Toronto, Canada, ...
... on science especially emerging technologies such as nanotechnology ... science policy released today argues. The group of leading ... that current governance activities are limiting public debate and ... DEEPEN report comes in the wake of a move ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... by Prof. Hardev Pandha of the Royal Surrey County ... online version of Clinical Cancer Research. The paper is ... in Murine Malignant Melanoma." , The research demonstrated that ...
Cached Biology Technology:Global Public Health the Focus of Scientific Conference 2Global Public Health the Focus of Scientific Conference 3Public must be involved in nanotech policy debate demands groundbreaking 2Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial 2
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/12/2015)... JOSE, Calif. , Aug. 12, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... recently announced Match-in-Sensor solution, have officially been named ... Alliance. As part of the certification, Synaptics, Natural ... FIDO 1.0 Universal Authentication Framework (UAF) standard and ...
(Date:8/10/2015)... LONDON , August 10, 2015 ... visiongain offers comprehensive analysis of the global border ... will generate revenues of $16.4bn in 2015. Now: ... This is an example of the business critical issue you ... to read visiongain ,s objective analysis of how this ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... New Rochelle, NY, June 28, 2013 Mary Ann Liebert, ... Printing and Additive Manufacturing , a highly innovative, peer-reviewed ... issue will publish in the fall of 2013, and ... the Director of Cornell University,s Creative Machines Lab at ...
... The world,s food supply got a little more plentiful thanks ... plant pathology at Kansas State University, and his colleague, Jorge ... that identified a gene that gives wheat plants resistance to ... rust pathogen -- called Ug99 -- that was first discovered ...
... 28 2013) A study carried out in India examining ... marrow stem cells in patients with type 2 diabetes ... compared to a control group of TD2M patients who ... The study appears as an early e-publication for the ...
Cached Biology News:Resistance gene found against Ug99 wheat stem rust pathogen 2Resistance gene found against Ug99 wheat stem rust pathogen 3Type 2 diabetes patients transplanted with own bone marrow stem cells reduces insulin use 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Immunogen: Fusion protein derived from ... ASIP/PAR-3 (atypical PKC isotype-specific interacting protein/ ... not related to the protease-activated-receptors also ... Xenopus (positive controls: Caco-2 MDCK A6 ...
... C-1-tetrahydrofolate synthase, ... [Includes: Methylenetetrahydrofolate dehydrogenase ... cyclohydrolase (EC 3.5.4.9); ... 6.3.4.3)]. [Source:Uniprot/SWISSPROT;Acc:P11586] ...
...
Biology Products: